Keilla Martins Milby1, Alvaro Nagib Atallah2, César Ramos Rocha-Filho3, Ana Carolina Pereira Nunes Pinto4, Aline Pereira da Rocha5, Felipe Sebastião de Assis Reis6, Nelson Carvas Junior7, Vinicius Tassoni Civile8, Rodolfo Rodrigo Pereira Santos9, Laura Jantsch Ferla10, Giulia Fernandes Moça Trevisani11, Gabriel Sodré Ramalho12, Maria Eduarda Dos Santos Puga13, Virgínia Fernandes Moça Trevisani14. 1. PhD. Nurse, Volunteer Researcher at Cochrane Brazil, São Paulo (SP), Brazil. 2. MD, MSc, PhD. Nephrologist and Full Professor, Discipline of Emergency and Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Director, Cochrane Brazil, São Paulo (SP), Brazil. 3. MSc. Biotechnologist and Doctoral Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. 4. MSc. Physiotherapist and Doctoral Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Professor, Biological and Health Sciences Department, Universidade Federal do Amapá (UNIFAP), Amapá (AP), Brazil; Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil. 5. MSc. Pharmacist and Doctoral Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil. 6. MD, MPS. Manager, Medical Practices, Beneficência Portuguesa de São Paulo, São Paulo (SP), Brazil. 7. Physical Educator, Universidade Ibirapuera, São Paulo (SP), Brazil. 8. MSc. Physiotherapist and Doctoral Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Assistant Professor, Physiotherapy Course, Universidade Paulista (UNIP), São Paulo (SP), Brazil; Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil. 9. Statistician and Master's Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Data Science Manager, Synova Health CRO, São Paulo (SP), Brazil. 10. Undergraduate Medical Student, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. 11. Undergraduate Medical Student, Universidade Santo Amaro (UNISA), São Paulo (SP), Brazil. 12. Undergraduate Medical Student, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. 13. MSc, PhD. Librarian, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil. 14. MD, MSc, PhD. Rheumatologist, Discipline of Emergency and Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil; Rheumatologist, Discipline of Rheumatology, Universidade Santo Amaro (UNISA), São Paulo (SP), Brazil.
Abstract
BACKGROUND: The numbers of cases of arboviral diseases have increased in tropical and subtropical regions while the coronavirus disease (COVID-19) pandemic overwhelms healthcare systems worldwide. The clinical manifestations of arboviral diseases, especially dengue fever, can be very similar to COVID-19, and misdiagnoses are still a reality. In the meantime, outcomes for patients and healthcare systems in situations of possible syndemic have not yet been clarified. OBJECTIVE: We set out to conduct a systematic review to understand and summarize the evidence relating to clinical manifestations, disease severity and prognoses among patients coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and arboviruses. METHODS: We conducted a rapid systematic review with meta-analysis, on prospective and retrospective cohorts, case-control studies and case series of patients with confirmed diagnoses of SARS-CoV-2 and arboviral infection. We followed the Cochrane Handbook recommendations. We searched EMBASE, MEDLINE, Cochrane Library, LILACS, Scopus and Web of Science to identify published, ongoing and unpublished studies. We planned to extract data and assess the risk of bias and the certainty of evidence of the studies included, using the Quality in Prognosis Studies tool and the Grading of Recommendations Assessment. RESULTS: We were able to retrieve 2,407 citations using the search strategy, but none of the studies fulfilled the inclusion criteria. CONCLUSION: The clinical presentations, disease severity and prognoses of patients coinfected with SARS-CoV-2 and arboviruses remain unclear. Further prospective studies are necessary in order to provide useful information for clinical decision-making processes. PROTOCOL REGISTRATION NUMBER IN THE PROSPERO DATABASE: CRD42020183460.
BACKGROUND: The numbers of cases of arboviral diseases have increased in tropical and subtropical regions while the coronavirus disease (COVID-19) pandemic overwhelms healthcare systems worldwide. The clinical manifestations of arboviral diseases, especially dengue fever, can be very similar to COVID-19, and misdiagnoses are still a reality. In the meantime, outcomes for patients and healthcare systems in situations of possible syndemic have not yet been clarified. OBJECTIVE: We set out to conduct a systematic review to understand and summarize the evidence relating to clinical manifestations, disease severity and prognoses among patients coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and arboviruses. METHODS: We conducted a rapid systematic review with meta-analysis, on prospective and retrospective cohorts, case-control studies and case series of patients with confirmed diagnoses of SARS-CoV-2 and arboviral infection. We followed the Cochrane Handbook recommendations. We searched EMBASE, MEDLINE, Cochrane Library, LILACS, Scopus and Web of Science to identify published, ongoing and unpublished studies. We planned to extract data and assess the risk of bias and the certainty of evidence of the studies included, using the Quality in Prognosis Studies tool and the Grading of Recommendations Assessment. RESULTS: We were able to retrieve 2,407 citations using the search strategy, but none of the studies fulfilled the inclusion criteria. CONCLUSION: The clinical presentations, disease severity and prognoses of patients coinfected with SARS-CoV-2 and arboviruses remain unclear. Further prospective studies are necessary in order to provide useful information for clinical decision-making processes. PROTOCOL REGISTRATION NUMBER IN THE PROSPERO DATABASE: CRD42020183460.
Authors: Juan Fidel Osuna-Ramos; José Manuel Reyes-Ruiz; Luis Antonio Ochoa-Ramírez; Luis Adrián De Jesús-González; Rosalío Ramos-Payán; Carlos Noe Farfan-Morales; Alejandra Romero-Utrilla; Efrén Rafael Ríos-Burgueño; José Rodríguez-Millán; Rosa María Del Ángel; Jesús Salvador Velarde-Félix Journal: Trop Med Infect Dis Date: 2022-01-30
Authors: Yordi Tarazona-Castro; Lucinda Troyes-Rivera; Johanna Martins-Luna; Felipe Cabellos-Altamirano; Miguel Angel Aguilar-Luis; Hugo Carrillo-Ng; Luis J Del Valle; Sungmin Kym; Sebastian Miranda-Maravi; Wilmer Silva-Caso; Saul Levy-Blitchtein; Juana Del Valle-Mendoza Journal: PLoS One Date: 2022-04-08 Impact factor: 3.240